Gravar-mail: Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression among Participants Initiating Antiretroviral Treatment with CD4+ Counts > 500 cells/mm(3): Findings from the Strategic Timing of AntiRetroviral Treatment (START) Trial